{"id":42795,"date":"2015-09-17T00:00:00","date_gmt":"2015-09-16T22:00:00","guid":{"rendered":"https:\/\/techma.bakertilly.es\/novedades-inversion-biotecnologia-septiembre-2015\/"},"modified":"2025-03-12T11:34:09","modified_gmt":"2025-03-12T10:34:09","slug":"novedades-inversion-biotecnologia-septiembre-2015","status":"publish","type":"post","link":"https:\/\/techma.bakertilly.es\/en\/novedades-inversion-biotecnologia-septiembre-2015\/","title":{"rendered":"Biotech investment news September 2015: CaixaIpulse, Sanifit and Centauri Biotech"},"content":{"rendered":"<address><span style=\"color: #000000;\">Good news for funding in the biotech sector in the first half of September, the largest round of funding in the history of Spanish biotechnology has been closed. CaixaImpulse has already announced its first 15 companies.<\/span><!--more--><\/address>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #3366ff;\"><strong>First edition of CaixaImpulse <\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\">A few months ago, in a post on new funds, we announced the appearance of the<span style=\"text-decoration: underline;\"> CaixaImpulse, <\/span>an initiative of CaixaCapitalRisk for the creation of companies in the scientific field and yesterday, 15th September, the 15 projects selected in the first edition from among the 41 presented by different research centres, hospitals and universities were announced.<\/span><\/p>\n<p><span style=\"color: #000000;\">\u00a0For the selection of the projects, which belong to various communities: Andalusia (1), Catalonia (11), Galicia (1) Madrid (1) and Navarre (1), priority was given to the transfer potential of the assets and their impact on society.<\/span><\/p>\n<p><span style=\"color: #000000;\">To guarantee the success of the projects, CaixImpulse offers financial support (\u20ac50,000), training tailored to their needs and a<strong>\u00a0<\/strong>immersion in market reality<strong>\u00a0<\/strong>which will allow them to test their asset value proposition, adapt it and thus maximise the likelihood of a successful transfer.<\/span><\/p>\n<p><span style=\"color: #000000;\">Among the projects that have been selected we find a project from<span style=\"text-decoration: underline;\">l CIMA<\/span> which focuses on <strong>\u00a0<\/strong>The project will focus on the development of a new drug effective against haemorrhage and a project of the Institute for Bioengineering of Catalonia, which focuses on the treatment of chronic ulcers.<\/span><\/p>\n<p><span style=\"color: #3366ff;\"><strong>I2c Fund acquires Centauri Biotech<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\">The Xunta de Galicia's venture capital company, Xesgalicia, has supported, through its I2C Fund, the biotech company <a href=\"http:\/\/www.centauribiotech.com\/\" target=\"_blank\" rel=\"noopener\">Centauri Biotech,<\/a> which develops veterinary pharmaceuticals.<\/span><\/p>\n<p><span style=\"color: #000000;\">I2C has taken a 15% stake in the biotech company after subscribing for 50% of a capital increase of 350,000 euros.<\/span><\/p>\n<p><span style=\"color: #000000;\">Centauri Biotech, which they see as having great growth potential, is working on the development of drugs and treatments based on cell therapy and genetic diagnostics for inflammatory or degenerative joint-related lesions in animals. The company was founded in 2012 by four researchers.<\/span><\/p>\n<p><span style=\"color: #000000;\">\"<span style=\"text-decoration: underline;\"><span class=\"removed_link\" title=\"http:\/\/www.xesgalicia.org\/\">Xesgalicia <\/span><\/span>I was already involved in another biotech company, Health in Code , a technology-based company that aims to identify health problems through the use of genetic diagnostics\" says Diego Gutierrez of<a href=\"https:\/\/techma.bakertilly.es\/en\/\"> Abra-Invest.<\/a><\/span><\/p>\n<p><span style=\"color: #3366ff;\"><strong>Sanifit closes a \u20ac36M round<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"text-decoration: underline;\"><span class=\"removed_link\" title=\"http:\/\/www.sanifit.com\/web\/\">Sanifit Laboratories<\/span>,<\/span> a biopharmaceutical company dedicated to the development of a <a href=\"http:\/\/www.elmundo.es\/economia\/2014\/04\/14\/53481aa0e2704e66568b4586.html\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000;\">drug for the treatment of cardiovascular diseases<\/span><\/a>\u00a0related to calcification in dialysis-treated End Stage Renal Disease (ESRD) patients, has closed a \u20ac36.6m round led by Ysios Capital, with the participation of several international investors.<\/span><\/p>\n<p><span style=\"color: #000000;\">\"This transaction is the largest round of financing for a Spanish company in the history of the biotech sector in Spain and one of the 10 largest in Europe so far this year,\" says Diego Gutierrez.<\/span><\/p>\n<p><span style=\"color: #000000;\">The capital increase will allow Sanifit to advance the clinical development of SNF472 to the end of phase IIb for the treatment of calcification-related cardiovascular diseases in patients with TRED and to phase II\/III for the treatment of calciphylaxis.<\/span><\/p>\n<p><span style=\"color: #000000;\">If you are looking for financing, contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Fill in the form or call us on +34 946024142<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><strong><span style=\"color: #3366ff;\">Other posts that may interest you\u00a0<\/span><\/strong><\/p>\n<p><span style=\"text-decoration: underline;\"><a href=\"https:\/\/techma.bakertilly.es\/en\/financiacion-para-el-sector-biotecnologico\/\">Investment for the biotech sector: Tigenix, Ekuore and Grants4Apps<\/a><\/span><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Good news for funding in the biotech sector in the first half of September, the largest round of funding in the history of Spanish biotechnology has been closed. CaixaImpulse has already announced its first 15 companies.<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1750],"tags":[238,375],"sectores":[],"tipo-contenido":[2260],"class_list":["post-42795","post","type-post","status-publish","format-standard","hentry","category-financiacion-sectorial","tag-biotecnologia","tag-financiacion-para-empresa-biotecnologica","tipo-contenido-noticias"],"acf":[],"_links":{"self":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/comments?post=42795"}],"version-history":[{"count":0,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42795\/revisions"}],"wp:attachment":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/media?parent=42795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/categories?post=42795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tags?post=42795"},{"taxonomy":"sectores","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/sectores?post=42795"},{"taxonomy":"tipo-contenido","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tipo-contenido?post=42795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}